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Abstract
The potential of anaflatoxin B1 (AnAFB1) conjugated to keyhole limpet hemocyanin (KLH) as a vaccine (AnAFB1-KLH) in
controlling the carry over of the aflatoxin B1 (AFB1) metabolite aflatoxin M1 (AFM1) in cow milk is reported. AFB1 is the most
carcinogenic compound in food and foodstuffs amongst aflatoxins (AFs). AnAFB1 is AFB1 chemically modified as AFB1-1(O-
carboxymethyl) oxime. In comparison to AFB1, AnAFB1 has proven to be non-toxic in vitro to human hepatocarcinoma cells
and non mutagenic to Salmonella typhimurium strains. AnAFB1-KLH was used for immunization of cows proving to induce a
long lasting titer of anti-AFB1 IgG antibodies (Abs) which were cross reactive with AFB1, AFG1, and AFG2. The elicited anti-
AFB1 Abs were able to hinder the secretion of AFM1 into the milk of cows continuously fed with AFB1. Vaccination of
lactating animals with conjugated AnAFB1 may represent a solution to the public hazard constituted by milk and cheese
contaminated with AFs.
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Introduction
Mycotoxins are secondary metabolites produced by molds,
classified among the most important risk factors in the food
chain of humans and animals. The problem of mycotoxicoses is
global and is particularly affecting the countries characterized by
environmental and weather conditions favourable to contamina-
tion and growth of fungi both in field and storage of stocks. It has
been estimated that 25% of the world’s food crops is contaminated
with mycotoxins, and more than 4.5 billion people and an
undefined number of animals are chronically exposed to aflatoxins
(AFs), the most relevant mycotoxins of medical interest [1,2]. AFs
(AFB1, AFB2, AFG1, AFG2), produced mainly by strains of
Aspergillus flavus and A. parasiticus, may cause acute (hepatitis,
oedema, hemorrhagic necrosis) or chronic (liver, lung, and kidney
carcinomas and immunosuppression) toxic effects [2]. The main
AF, AFB1, has a range of biological activities, including acute
toxicity, teratogenicity, mutagenicity and carcinogenicity [3].
The International Agency for Research on Cancer (IARC)
has classified AFB1 as the most important known carcinogenic
compound (group 1), particularly related to hepatocarcinoma
[4,5].
In animal farming, AFs may cause reduced performance,
increased susceptibility to infections, altered responsiveness to
vaccinations [6], in addition to contamination of derived dietary
products such as meat, eggs and milk [7,8]. Following ingestion of
contaminated feed, AFB1 is rapidly adsorbed and transported to
the liver where it is partially metabolized into the hydroxy-derivate
M1, which may be secreted in the milk of mammals, including
dairy animals (carry over process) [9,10]. AFM1, which is as toxic
as AFB1, has been included in Group 2 (potentially carcinogenic
for humans) by IARC [4]. By association with casein, AFM1
occurring in the milk concentrates during cheese making, thus
increasing the risk potential of the milk/cheese production chain
[11].
Industrialized countries have defined specific limits for AFM1 in
the milk destined for human consumption (ranging from 0.05 mg
AFM1/kg of the European Community to 0.5 mg/kg of USA), and
for AFB1 in dairy animal feeds [12]. The best strategy to counter
the AFs problem is the prevention of fungal contamination in the
food chain. When outbreaks of AFs occur, some means of
salvaging contaminated feeds involve physical or chemical
detoxifying methods or inclusion in the diet of a variety of animals
of sequestering agents, able to prevent AFs absorption in the
gastro-intestinal tract [13]. However, none of these methods fulfill
completely the efficacy, safety, and cost requisites of the task [14].
The production of a vaccine able to induce specific antibodies
(Abs) neutralizing AFB1 and other AFs would be of great social,
scientific and economic interest. Conventional vaccine approaches
are not feasible due to the non immunogenicity of AFB1. Its
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conjugation to proteins, shown to be effective with other haptens,
would be unlikely for human use and hardly proposable in
animals, owing to the toxic properties of the molecule that might
be released. A modified form of AFB1 (anaflatoxin B1, AnAFB1),
devoid of toxicity and mutagenicity, still maintaining antigenicity
when conjugated, would be a potential vaccine candidate. A
method for the preparation and purification of AFB1-1(O-
carboxymethyl) oxime from AFB1 has been described, and the
derivative was shown to be nontoxic to chicken embryos [15].
Lower mortality and reduction of acute toxic effects in the liver
was achieved in rabbits and rats immunized with AFB1-1(O-
carboxymethyl) oxime conjugated to bovine serum albumin (BSA)
or histone H1 and challenged with a single dose of AFB1
[16,17,18].
The aim of this study was to evaluate whether AnAFB1,
represented by AFB1-1(O-carboxymethyl) oxime, verified in vitro to
be nontoxic to human hepatocarcinoma cells and non mutagenic
to Salmonella typhimurium strains, might constitute, following
conjugation to a non-bovine protein (KLH), a potential vaccine
to prevent the carry over of AFB1 as AFM1 in the milk of dairy
cows receiving an AFB1-contaminated diet.
Results
Cytotoxicity assay of AFB1 and AnAFB1 on HepG2 cells
The effects of a range of concentrations of AFB1 and AnAFB1
on the viability of HepG2 hepatoblastoma cells were evaluated by
a colorimetric assay. AFB1 caused a dose-dependent cytotoxicity,
as survival of the cells inversely decreased with increases in the
concentration of AFB1 from 1.1 to 22 mg/ml (Figure 1A). Cells
exposed to AnAFB1 showed no significant decrease in cell viability
at concentrations up to 110 mg/ml (Figure 1B).
In vitro mutagenicity assay of AFB1 and AnAFB1 in
Salmonella typhimurium
The Ames test with strains TA 98 and TA 100 was carried out in
order to elucidate whether AnAFB1 retained the mutagenic properties
of AFB1. The results of the mutagenicity assay are shown in Table 1.
AnAFB1, up to a concentration of 200 ng/plate, did not elicit a
mutagenic response either in S. typhimurium TA98 or TA 100. At
the concentration of 500 ng/plate, a positive, but very weak,
mutagenic activity was observed only in S. typhimurium TA 100,
while the positive control AFB1 induced a strong mutagenic
response at concentrations of 100 and 200 ng/plate.
ELISA titration of anti-AFB1 Abs
Production of Abs against AFB1 in vaccinated and control dairy
cows was evaluated by ELISA. For all of the cows, dilutions of pre-
immune control sera showed negligible binding to AFB1-BSA.
When dilution series of cow sera were incubated with control BSA
(unconjugated), only a low degree of nonspecific binding was
detected (data not shown). Control cows (6 out of 6) did not produce,
as expected, anti-AFB1 Abs (data not shown). Ab titers of vaccinated
cows over a 10-week period are presented in Figure 2. Based on the
anti-AFB1 Ab titer, at the 10
th week it was possible to differentiate
two groups among vaccinated cows. Animals producing the highest
serum titers ranging from 10,000 to 40,000 were defined as ‘‘high
responders’’ (cow number 322, 335, 338). The animals presenting
titers ranging from 1,000 to 4,000 were defined as ‘‘low responders’’
(cow number 348, 363, 366). Following immunization none of the
animals provided positive reactions to the intradermal tuberculin
test as attested by the local competent authority.
Cross-reactivity of anti-AFB1 Abs with other AFs
Sera from the 10th week bleeding were selected for cross-
reactivity evaluation with AFs. The cross-reactivity of immune sera
Figure 1. In vitro effects of AFB1 (A) and AnAFB1 (B) on human hepatoblastoma cell viability.
doi:10.1371/journal.pone.0026777.g001
Table 1. Mutagenicity of AFB1 and AnAFB1 in S. typhimurium
TA98 and TA100.
dose his+ revertants*
(ng/plate) TA 98 TA 100
AFB1 0 662 25622
100 175631 133621
200 307649 622647
AnAFB1 0 662 25622
100 261 26614
200 262 562
500 462 59625
*mean of two independent, triplicate mutagenicity assays with SD.
doi:10.1371/journal.pone.0026777.t001
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collected from each cow with AFB2, AFG1, and AFG2 was similar
and averaged 17%, 31%, and 9%, respectively (Table 2). AFM1
displayed negligible cross-reactivity for all the immune sera, since
50% inhibition of binding to AFB1-BSA was not reached using
concentrations up to 1000 ng/ml.
Quantification of AFM1 in milk samples
The efficacy of anti-AFB1 Abs in preventing or reducing the
carry over of AFB1 as AFM1 into milk was evaluated by
monitoring AFM1 concentrations in milk of the lactating dairy
cows. An intermittent exposure regimen with two intoxication
periods was designed to evaluate efficacy of anti-AFB1 Abs over
time and in two different lactation (mid and late) stages.
Basal diet AFB1 level contributed to a milk AFM1 contamina-
tion of 12.161.3 and 16.866.6 ng/kg in the first and second
period, respectively (as calculated on day 0). Results of AFM1
quantification in the milk collected during the first intoxication
period (144 mg AFB1 per cow per day) are shown in Figure 3. At day
1, the milk sampled from the control cows had an AFM1
concentration higher than the tolerable level allowed by the EC
(0.05 mg/kg) [19]. On the contrary, the milk samples collected
from vaccinated cows had an AFM1 concentration lower than
control milk and below the EC maximum allowed level. However,
the AFM1 concentration in milk increased at every milking and
reached a steady-state condition from day 7 of intoxication period
for both groups. On day 11, when AFB1 administration was
stopped, the mean AFM1 concentration decreased quickly to
return at the base line on day 16. During the experimental period,
the milk of vaccinated cows consuming contaminated feed showed
AFM1 levels always lower (even non statistically significant) than
the milk of control animals. In particular, at the steady state
condition, the average AFM1 concentration in milk collected from
vaccinated cows was 20% lower than in milk of control animals
(137 ng/kg vs 171 ng/kg). A negative correlation between serum
AFB1 specific Ab titers and the average concentration of AFM1
detected in the milk at the steady state condition during the first
experimental period (r =20.72, p,0.05) was observed in
vaccinated cows. Importantly, the ‘‘high responder’’ cows,
showing the highest titers of anti-AFB1 Abs, produced an average
milk AFM1 concentration at the steady state about 46% lower
(p,0.05) than control cows (95 ng/kg vs 177 ng/kg; Figure 4).
During the second experimental period, AFM1 in milk from
vaccinated cows consuming the contaminated feed (145 mg AFB1
per cow per day) showed the same trend as in first experimental
period, with AFM1 levels always lower (even non statistically
significant) than that of control cows consuming AFB1. In
particular, at the steady state condition, average AFM1 concen-
tration in milk collected from vaccinated cows was 11% lower than
in milk of control animals (134 vs 154 ng/kg, respectively)
(Figure 5). Similarly to first exposure period, the average
Figure 2. Titers of anti-AFB1 Abs. Cows numbered 322, 335, 338, 348, 363 and 366 were initially i.m. primed with 500 mg of AnAFB1-KLH
conjugate and then boosted at week 3, 6 and 9 with the same amount of immunogen. Ab titers (presented in figure on a logarithmic scale) were
determined by the method described in the text.
doi:10.1371/journal.pone.0026777.g002
Table 2. Cross-reactivity of immune sera with AFs.
Cow number
322 335 338 348 363 366
AF IC50
* % IC50 % IC50 % IC50 % IC50 % IC50 % % average
AFB1 76.69 100 28.06 100 150.80 100 58.96 100 66.11 100 48.41 100 100
AFB2 496.10 15 213.50 13 990.00 15 301.50 20 282.40 23 393.30 12 17
AFG1 339.60 23 126.70 22 502.90 30 253.10 23 167.40 39 100.70 48 31
AFG2 906.70 8 480.70 6 848.70 18 2611.00 2 730.50 9 405.70 12 9
*IC50 is the AF concentration (ng/ml) causing 50% inhibition of binding of the immune serum to the solid phase.
doi:10.1371/journal.pone.0026777.t002
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concentration of AFM1 in milk at the steady state condition was
correlated (r =20.68, p,0.05) with anti-AFB1 Ab titers in the
serum of vaccinated cows, with average AFM1 concentration in
milk of ‘‘high responder’’ cows 37% lower (p,0.05) of that
observed in control cows (97 vs 154 ng/kg, respectively; Figure 6).
Discussion
The occurrence of AFM1 in milk and its derivatives is a serious
problem of food safety, as milk is a primary source of human
nutrition, in particular for infants and children. To reduce human
and animal exposure, industrialized countries have defined specific
limits for AFM1 in the milk and for AFB1 in the feed of dairy
animals [12]. Currently, the best strategy in order to avoid
exceeding of the maximum limit of AFM1 in the milk destined for
human consumption is the prevention of AF contamination of
feeds, but in spite of the control measures taken, production of
AFM1-free milk is not always achieved. In industrialized countries
the milk having higher levels of contamination than the current
legal limits is destroyed, although exposure to low doses of AFM1,
which could be present beneath that limit, is not prevented, with
potential health effects due to accumulation. Moreover, in
developing countries, where food availability has often to be
considered before food safety, there is a lack of legislation of
Figure 3. Average AFM1 concentration in milk collected during the first experimental period. Six vaccinated (&) and six control (m) cows
were fed 144 mg of AFB1/day from day 1 to day 11. Data are presented as mean 6 SD.
doi:10.1371/journal.pone.0026777.g003
Figure 4. Average AFM1 concentrations in milk collected during the first experimental period from high responder cows. Three high
responder vaccinated cows (¤) and six control cows (m) were fed 144 mg of AFB1/day from day 1 to day 11. Data are presented as mean 6 SD.
doi:10.1371/journal.pone.0026777.g004
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acceptable limits for AFs and populations are undoubtedly
exposed to high amounts of AFM1 in milk.
An alternative management of the problem, therefore, could
rely on a preventive approach such as a safe and reliable vaccine
for dairy cattle which should be effective in avoiding AFB1 carry
over in the milk.
We report here the proof-of-concept that AnAFB1, composed of
AFB1-1(O-carboxymethyl) oxime, which proved to be non toxic
and non mutagenic in controlled experimental conditions, may
fulfill with the purpose. AnAFB1 conjugated to a carrier protein
(KLH) and with Freund’s adjuvant elicited in cows cross-reactive
anti-AFs long lasting Ig, mostly pertaining to IgG, although other
Ig classes could contribute to observed results, since the Abs used
to detect anti-AFB1 Abs were not gamma chain specific. Anti-AFs
Abs proved to substantially reduce AFB1 carry over as AFM1 in
the milk for a prolonged period of ingestion of contaminated feed.
No adverse effect on animal health was observed in AFB1 exposed
cows, consistently with previous works adopting similar contam-
ination levels [20,21]. It is notable that a single administration of
the vaccine in complete Freund’s adjuvant did not induce delayed
hypersensitivity in any of the vaccinated cows, as demonstrated by
negative intradermal tuberculin test. This finding should exclude
any misleading evaluation of livestock health.
According to Ab titer specific for AFB1, it was possible to
recognize, among the 6 vaccinated cows, 3 high responder and 3
low responder animals. The titer of Abs specific to AFB1 in
vaccinated cows correlated well with the prevention of carry over
in the milk, following exposure of the cows to feed contaminated
Figure 5. Average AFM1 concentrations in milk collected during the second experimental period. Six vaccinated (&) and six control (m)
cows were fed 145 mg of AFB1/day from day 1 to day 11. Data are presented as mean 6 SD.
doi:10.1371/journal.pone.0026777.g005
Figure 6. Average AFM1 concentrations in milk collected during the second experimental period from high responder cows. Three
high responder vaccinated cows (¤) and six control cows (m) were fed 145 mg of AFB1/day from day 1 to day 11. Data are presented as mean 6 SD.
doi:10.1371/journal.pone.0026777.g006
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with AFB1. Cows of the high responder group (titers ranging from
10,000 to 40,000) presented, at the steady state, significantly lower
concentrations of AFM1 in the milk than cows of the low
responder group (titers ranging from 1,000 to 4,000). Moreover,
the anti-AFB1 Abs elicited in the high responder cows appeared to
reduce the excretion of AFM1 in the milk following intoxication
either in the mid or late lactation stages, thus conferring protection
over the whole production cycle, before the drying off period.
The reasons why healthy, immunocompetent animals may be
differently susceptible to immunization are not well understood,
but it has been reported that cows could be phenotypically
classified as low or high responders, based on the magnitude and
kinetics of the Ab response to injection of various antigens
[22,23,24]. Recognized factors of variation in cows’ responsiveness
to immunization include, among others, the energy balance
derived from feeding regimen, peripartum stress and lactation
stage [22,23,24]. In addition to these non-genetic effects, there is
growing evidence that the individual’s genotype may predetermine
immunological responses to infection and vaccination [23,24,25].
The Ab response to immunization also appears to be often
dependent on the adjuvant adopted. Currently, the exact
mechanism of action of many adjuvants is still unknown, and
research continues to strive to identify the best adjuvant or
combination of adjuvants to elicit the correct immune response for
a given antigen [26]. Furthermore, selection of carrier proteins
used in haptenic vaccines has proven to be greatly important in
eliciting potent anti-hapten Ab because it exerts a clear influence
on the immune response [27]. It is therefore possible that
appropriate vaccine formulations (e.g. different adjuvants or
carriers) could stimulate the immunity and surmount deficiencies
in low responder cows.
Reduction of AFM1 in milk obtained in high responder
vaccinated cows was comparable with reductions obtained adding
to animal diet the best AFs sequestering agents, which are able to
reduce AFM1 transfer in the milk up to 50%, depending on
the extent of contamination [28,29]. The results obtained by
vaccination, moreover, could be cumulated with the ones even-
tually achieved by adopting alternative treatments.
Easy detection of anti-AFB1 Abs could allow monitoring the
immunological status of milk animals in order to determine the
protective titre and evaluate the need for booster injections.
Although the schedule of immunization, the nature of adjuvant
and carrier, the requirement for boosters and some other factors,
such as the fate of AFB1 captured by antibodies, should be
furtherly investigated, conjugated AnAFB1 may represent a
possible solution to a global and serious health problem.
Materials and Methods
Ethics statement
The research protocol and animal care were in accordance
with the EC Council Directive guidelines for animals used for
experimental and other scientific purposes [30].
The study has been approved by the local health autority
‘‘Azienda Unita` Sanitaria Locale di Piacenza’’ (protocol number
24567) and by the National Ministry of Health according to
legislative decree 116/92.
Preparation of AnAFB1
AFB1 (Sigma-Aldrich, Inc., St. Louis, MO, USA) was con-
verted to AFB1-1(O-carboxymethyl) oxime using a method pre-
viously described [15]. Briefly, carboxymethylhydroxylamineNHCl
(10 mg, 0.046 mmol) was added to a solution of AFB1 (10 mg,
0.032 mmol) in methanol/water/pyridine (4:1:1) and the mixture
was refluxed at 60uC for 3 h. After maintenance overnight
at room temperature, the solution was concentrated under
vacuum. The product was purified by flash chromatography
(CHCl3:MeOH=7:3), and confirmed to be AFB1-1(O-carbox-
ymethyl) oxime by UPLC/MS (Acquity, Waters, Milford, MA,
USA). The UPLC separation was performed on a reversed-phase
C-18 column (UPLC BEH Aquity, Waters; 17 mm621 mm),
eluted at a flow rate of 300 ml/min. Mobile phase consisted of
0.2% formic acid in H2O (solvent A) and 0.2% formic acid in
acetonitrile (solvent B).
Cytotoxicity assay of AnAFB1 on HepG2
Human hepatoblastoma (HepG2) cell line (BS-TCL-79, ATCC,
Rockville, MD, USA) was maintained in tissue culture flasks with
Dulbecco’s modified Eagle’s medium (DMEM) (Sigma-Aldrich)
containing 10% fetal calf serum, 1% antibiotics (10,000 U/ml
penicillin, 10,000 U/ml streptomycin sulfate), 1% glutamine, and
1 mM sodium pyruvate (Life Technologies, Gaithersburg, MD,
USA). Cells were cultured in a humidified incubator under 5%
CO2 at 37uC and split twice a week. Cell viability was assessed by
spectrophotometrically measuring alamarBlue (AB) (Biosource
International Inc., Camarillo, CA, USA) reduction by mitochon-
drial enzyme activity [31]. The day before treatment HepG2 were
trypsinized and seeded at a density of 56104 cells/well in flat
bottom 96-wells plates (Costar, Corning Inc., Corning, NY, USA).
After 24 h incubation under 5% CO2 at 37uC, the medium in
each well was discarded and replaced by fresh medium containing
increasing dilutions of AnAFB1 or AFB1, obtained from stock
solutions prepared in dimethylsulfoxide (DMSO). All experiments
included both untreated and solvent control cultures. After 24 h of
treatment, the medium was discarded and cells were washed twice
with PBS. Cells were then incubated for 2 h at 37uC under 5%
CO2 in 100 ml of incubation medium along with 10% (v/v) AB.
Absorbance values were measured at 570/595 nm with a Sunrise
Absorbance Reader (Tecan Italia Srl., Milan, Italy). The values
were corrected for background of negative controls containing
medium without cells. Treated cell viability was calculated in
comparison to untreated cultures, assumed to be 100%.
In vitro mutagenicity assay of AnAFB1 in Salmonella
typhimurium
Mutagenicity of AnAFB1, in comparison with AFB1, was
assessed in the reverse mutation assay by the standard plate
incorporation method developed by Maron and Ames [32]. The
compounds were tested on His2 S. typhimurium TA 98 and TA 100
(kindly donated by Dott. Cassoni, ARPA, Parma, Italy) with in vitro
extracellular microsomal activation (S9 from Aroclor 1254-
induced rats, Moltox Inc., Boone, NC, USA). Overnight cultures
of the test strains were grown for 8–16 h in Nutrient Broth
n.2 (Fluka Chemika, Buchs, Switzerland) to a cell density of
approximately 109 CFU/ml. Three concentrations (100, 200 and
500 ng/plate) for AnAFB1 and two concentrations (100 and
200 ng/plate) for AFB1 were tested, with three replicate plates at
each dose. The compounds were dissolved in DMSO and diluted
in distilled water immediately prior to testing. 0.1 ml each of the
test sample and bacterial suspension with 0.5 ml PBS (pH 7.4) or
0.5 ml of the metabolic system S9 were added to 2 ml of molten
top agar (45uC) supplemented with 0.05 mM L-histidine and
0.05 mM d-biotin and subsequently poured onto minimal glucose
agar plates (15 ml/plate). After 48 h at 37uC the colonies (His+
revertants) in each plate were counted. Solvent alone served as
negative control (spontaneous mutation frequency) while AFB1
was included as a positive control [33]. A mutagenic potential was
assumed, if a two-fold or greater increase was seen in the number
Vaccine against Aflatoxin Carry Over in Cow’s Milk
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of revertant colonies of the treated cultures in comparison to
negative controls.
Conjugation of AnAFB1 to KLH
AnAFB1 was conjugated to KLH (Sigma-Aldrich) to be used as
immunogen. The coupling reaction was carried out using a
method previously described [34]. N-hydroxysuccinimide (1.1 mg)
and N,N9-diisopropylcarbodiimide (1.45 ml), dissolved in 600 ml of
dimethylformamide (DMF), were added to AnAFB1 (2 mg) in
600 ml of dry dichloromethane at 0uC, followed by 4-(dimethyla-
mino)pyridine (1 mg). Then, the active ester was slowly added to a
pre-cooled aqueous buffered solution (31 mM Na2HPO4, pH 9.1)
containing 20 mg KLH and not more than 10% (v/v) DMF. The
mixture was kept at 4uC overnight, and then the conjugate was
separated from unreacted reagents and byproducts, desalted and
extensively dialyzed against PBS by using a 10 kDa cut-off
centrifugal filter tube (Microcon YM-10, Millipore Corporation,
Bedford, MA, USA). The protein concentration was determined
by using the Bradford method, using BSA (Sigma-Aldrich) as
external standard. In order to estimate the AFB1 loading on KLH,
UV absorbance was measured at 363 nm, assuming that the
absorbance of the conjugated AFB1 was the same as the
unmodified toxin (e=21,800 L?mol21?cm21). The ratio between
the concentration of the bound toxin and that of the protein gave
the loading degree of the conjugate.
Animal immunization
Two groups of six multiparous lactating Holstein Friesian dairy
cows were used in the present study. Cows were housed in a
free stall barn (CERZOO research and experimental centre,
San Bonico, Italy) and had free access to water. The diet was
formulated according to the nutrient requirements of dairy cattle
for an average cow weighting 650 kg, 140 days in milk (DIM) and
a 35 kg milk yield (3.8% fat and 3.35% protein) [35]. The diet,
composed both by forages and concentrate (total mixed ration),
was fed ad libitum. Cows were milked twice a day and individual
milk yield was recorded at every milking (Afimilk system, S.A.E.
Afikim, Kibbutz Afikim, Israel). The animals were regularly
inspected by the local competent authority; official intradermal
tuberculin test was carried out and interpreted according to EC
Commission Regulations [36]. Each cow was immunized by
intramuscular (i.m.) neck injection with an 1 ml emulsion of
500 mg of either AnAFB1-KLH (vaccinated animals) or KLH
(control animals) in complete Freund’s adjuvant (Sigma-Aldrich) in
a 1:1 (v/v) ratio. Priming injection was done at 85621 DIM and
was followed by three similar dose booster injections in incomplete
Freund’s adjuvant at three week intervals. Animals were bled via
the jugular artery prior to immunization and weekly thereafter.
The blood was allowed to clot 60 min at 37uC, and the serum was
obtained by centrifugation (1500 g, 10 min) and stored at 220uC
until assay.
Enzyme-linked immunosorbent assay (ELISA)
For titration of specific antibody, wells of polystyrene microtiter
plates (Costar) were coated overnight (4uC) with 50 ml of AFB1-
BSA conjugate (Sigma-Aldrich) or BSA control protein, 20 mg/ml,
in 0.05 M sodium carbonate-bicarbonate buffer (pH 9.6). Plates
were washed at this point and after each incubation step with
100 ml of PBS containing 0.05% Tween 20. Wells were blocked
for 60 min at 37uC with 100 ml of 1% (w/v) gelatin from porcine
skin (Type A; Sigma-Aldrich) in PBS. To each well, 50 ml of
serially diluted immune serum or control (pre-immune serum) was
added, gently mixed, and incubated at 37uC for 90 min. 50 ml of
rabbit anti-bovine IgG (whole molecule) peroxidase conjugate Abs
(Sigma-Aldrich, product number A7414) diluted 1:25,000 in PBS
were added to each well. After 60 min incubation at 37uC, 50 ml
of freshly prepared cromogen/substrate solution, constituted by
1 mg of 3,39, 5,59-tetramethylbenzidine dihydrochloride and 2 ml
of 30% H2O2 in 10 ml of citric buffer (51 mM Na2HPO4, 24 mM
citric acid, pH 5.0), were added. The reaction was stopped after
ten minutes with 25 ml of 0.5 M H2SO4. The optical density (OD)
at 450 nm was read by using a Multiskan Ascent (Labsystems,
Helsinki, Finland) and the titer of each immune serum was defined
as the inverse of the highest dilution that gave 0.1 OD above the
pre-immune serum at the same dilution. To compensate for
between-plate variability, individual plates were normalized to the
mean of the appropriate positive control.
A competitive indirect ELISA (ci-ELISA) was used to assess the
cross-reactivity of anti-AFB1 Abs in cow’s sera with other AFs.
Microtiter plates were coated with AFB1-BSA and blocked as
described above. Increasing concentrations of AFB1, AFB2, AFG1,
AFG2, or AFM1 in 25 ml PBS were mixed with a 25 ml volume of
immune serum (diluted 1:400 in PBS) in the wells of the microtiter
plates and incubated for 1 h at 37uC. Bound Abs were determined
by the addition of anti-bovine IgG peroxidase conjugate as
described above. The absorbance in the assay without free AFs
was assumed as the maximal value. AF concentration causing 50%
inhibition (IC50) of binding of the immune serum to AFB1-BSA
was calculated by variable slope nonlinear regression analysis of
curves obtained by plotting the percent absorbance values versus
log AF concentration using GraphPhad Prism 4.01 software (San
Diego, CA, USA). The relative cross-reactivity of the immune
serum with different AFs was calculated as (IC50 of AFB1/IC50 of
other AF)6100.
Quantification of AFB1 in feeds
Ten grams of dried feed was suspended in 100 ml acetone:water
solution (85:15), shaken at 150 r.p.m. for 45 min (Universal table
Shaker 709, ASAL srl, Milan, Italy), filtered (Schleicher & Schuell
595K filter paper, Dassel, Germany), and 5 ml was loaded on an
immunoaffinity column (Aflatoxin Easy-extract, Rhone Diagnos-
tics Technologies, Glasgow, UK) and the column washed with
45 ml bidistilled water. The column was further washed with 5 ml
water and bound AFB1 eluted with 2.5 ml of methanol. The
extract was dried under nitrogen, redissolved in 1 ml acetonitrile:-
water (25:75) solution and filtered (Millipore Corporation; HV
0.45 mm). HPLC analysis was performed with a Perkin Elmer LC
(Perkin Elmer, Norwalk, CT, USA) equipped with an LC-200
pump and a Jasco FP-1520 fluorescence detector (Jasco, Tokyo,
Japan) set at 365 nm (excitation) and 440 nm (emission).
Calibration was performed as a function of standard AFB1
(Sigma-Aldrich) concentrations. Standard solutions were prepared
and checked according to the AOAC method 970.44 [37]. AFB1
was separated with a reverse-phase C18 Superspher column
(Merck, Darmstadt, Germany; 4 mm particle size, 12564 mm i.d.)
at room temperature, with water:acetonitrile:methanol (59:15:26)
mobile phase at a flow rate of 1 ml/min.
Treatment of dairy cows with AFB1
The study consisted of two successive intoxication periods: the
first, starting 1 week after the last booster injection, carried out at
mid lactation stage (155621 DIM, average milk yield of
32.165.6 kg/day per cow), and the second at late lactation stage
(246621 DIM, average milk production of 28.863.1 kg/day per
cow).
The basal diet had an AFB1 content of 0.50 mg kg
21 in the first
and 0.55 mg kg21 in the second experimental period, correspond-
ing to about 11.5–12.7 mg per cow per day based on an average
Vaccine against Aflatoxin Carry Over in Cow’s Milk
PLoS ONE | www.plosone.org 7 October 2011 | Volume 6 | Issue 10 | e26777
ingestion of 23 kg dry matter per cow per day. Corn meal naturally
hypercontaminated was diluted in about 300 g of AFB1-free soy
bean meal to obtain a bolus, which gave a calculated daily AFB1
total ingestion of 144 mg and 145 mg, respectively.
Experimental periods lasted 16 days, consisting of 11 days of
intoxication and 5 days of clearance (no AFB1 in the diet).
Individual milk samples were collected at day 0, 1, 3, 5, 7, 9, 11,
12, 14, and 16. A representative sample for each day of milking
was then obtained and stored at 218uC for subsequent analysis.
Basal diet samples were collected on days 0 and 11 of each
experimental period, dried at 55uC in a ventilated oven to constant
weight, and then ground with a 1 mm sieve (Thomas-Wiley
Laboratory Mill, Arthur H. Thomas Co., Philadelphia, PA, USA)
and frozen until analysed for AFs.
Quantification of AFM1 in milk samples
Milk samples (50 ml) were defatted by centrifugation
(7,000 r.p.m. for 10 min at 4uC) and filtered with Schleicher
& Schuell 595 K filter paper (Dassel). Then, 20 ml was passed
through the immunoaffinity column (Aflatoxin Easy-extract)
and AFM1 was quantified by HPLC, following separation with a
reverse-phase C18 LiChrosper 100 column (Merck, Darmstadt,
Germany; 5 mm particle size, 12564 mm i.d.) at room
temperature, with water:acetonitrile (75:25) mobile phase at a
flow rate of 1 ml/min. AFM1 (Sigma-Aldrich) was used as
calibration standard, as previously described for AFB1 quanti-
fication.
Statistical analyses
All data are presented as means 6 standard deviations (SD).
Differences between immunization groups and the results of the
cytotoxicity and mutagenicity assays were analysed using the
Student’s t test. Concerning the excretion pattern of AFM1 into
milk, the steady-state condition was determined in agreement to
Littell et al. [38]. AFM1 milk concentration at the plateau
condition was subjected to Analysis of Variance (ANOVA). The
statistical model included fixed effects of treatment, time of
measurement and the treatment6time of measurement interac-
tions, with cow as the random variable. Differences between
means were accepted as significant if p,0.05.
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